IMP welcomes European Commission approval of KYGEVVI® for TK2d
European Commission approves KYGEVVI® for TK2d IMP warmly welcomes the decision by the European Commission to approve KYGEVVI® (doxecitine and doxribtimine) as […]
KYGEVVI®
EMA grants positive CHMP opinion for KYGEVVI® for Treatment of TK2d
EMA grants positive CHMP opinion for Kygevvi® for Treatment of TK2d International Mito Patients (IMP) and the global mitochondrial disease community
IMP Welcomes FDA Approval of First-Ever Treatment for TK2d
IMP Welcomes FDA Approval of First-Ever Treatment for TK2d International Mito Patient (IMP) is delighted to welcome yesterday’s approval by